Faculty profile

Neil Fleshner

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Neil Fleshner

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
51 publications in the last five years, latest in 2026.
Senior (last) author on 13 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2018.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

212

Publications

620

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Active Surveillance Exosomal Mirnas Liquid Biopsy Prostate Cancer

Latest papers

External Validation and Comparison of Magnetic Resonance Imaging-based Risk Calculators for Detection of Clinically Significant Prostate Cancer: A Multi-institutional Study Incorporating Transrectal and Transperineal Biopsy Approaches.
European urology focus · 2026
Atypical intraductal proliferation in prostate biopsy - a diagnostic grey zone with clinical implications.
Nature reviews. Urology · 2026 · senior author
131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

All 212 publications

Latest funding

Development, multi-ancestry international validation, algorithmic audit, and prospective silent trial evaluation of PRISM - A globally accessible, patient-oriented artificial intelligence-based model to predict the presence of clinically significant prostate cancer
CIHR · 2023 · Co-investigator
$462,824
Development of the first pre-operative serum exosomal miRNA test to guide treatment decision in prostate cancer
CIHR · 2018 · Principal investigator
$573,752
Feasibility of integrating epigenomic and genomic liquid biopsy biomarkers into the clinical management of advanced prostate cancer
CIHR · 2018 · Co-investigator
$544,120

All 11 grants and awards

From the 150 most recent of 212 publications.

External Validation and Comparison of Magnetic Resonance Imaging-based Risk Calculators for Detection of Clinically Significant Prostate Cancer: A Multi-institutional Study Incorporating Transrectal and Transperineal Biopsy Approaches.

Zlotta AR, Taborek A, Kwong JCC, Wang A, Boulakia N, Yin LB, Zhang KK, Nguyen DD, Srigley JR, der Kwast TV, Prendeville S, Booth R, Shahid A, Ringa M, Ali A, Diamond I, Bruni S, Klotz LH, Perlis N, Fleshner N, Finelli A, Diamand R, Ghai S, Haider M, Buckley R, Feifer A, Mian BM, Kulkarni GS

European urology focus2026

DOI: 10.1016/j.euf.2026.06.027 PMID: 42763233

Atypical intraductal proliferation in prostate biopsy - a diagnostic grey zone with clinical implications.

Bernardino RM, Lobo J, Kaouk J, van der Kwast T, Prendeville S, Zattoni F, Bianchi L, Martini A, Rajwa P, Kasivisvanathan V, Marra G, Fleshner N, Young Academic Urologists Working Group Prostate Cancer Board

Nature reviews. Urology2026Senior author

DOI: 10.1038/s41585-025-01106-7 PMID: 41203847

131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.

Yu EY, Narayan V, Esposito G, Szmulewitz R, Lu Y, Lilly MB, Calais J, Bratslavsky G, Menda Y, Vasanawala M, Pouliot F, Laidley D, Fleshner N, Saad F, Provost JC, Teslenko I, Rawat NK, Ulaner G

Clinical cancer research : an official journal of the American Association for Cancer Research2026

DOI: 10.1158/1078-0432.ccr-25-4948 PMID: 41779000

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Uchil A, Lacombe L, Hovington H, Brisson H, Simonyan D, Caron P, Ouellet V, Latour M, Aprikian A, Bergeron A, Chevalier S, McKercher G, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Carmel M, Hamilou Z, Trudel D, van der Kwast T, Mes-Masson AM, Dong X, Saad F, Guillemette C, Lévesque E

European urology oncology2026

DOI: 10.1016/j.euo.2025.07.014 PMID: 40998686

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

Pace KJC, Kwong JCC, Randhawa H, Ringa M, Al-Daqqaq Z, Chelliahpillai Y, Lee S, Kim K, Haile S, Ali A, Wettstein M, Chan A, Perlis N, Lee J, Hamilton R, Fleshner N, Finelli A, Jamal M, Papanikolaou F, Short T, Feifer A, Kulkarni G, Zlotta AR

BJU international2026

DOI: 10.1111/bju.70085 PMID: 41260885

Author Correction: Atypical intraductal proliferation in prostate biopsy - a diagnostic grey zone with clinical implications.

Nature reviews. Urology2026Senior author

DOI: 10.1038/s41585-025-01114-7 PMID: 41249636

Analysis of upper tract urothelial carcinoma in the Asian population.

Qin S, Lim K, Tempo J, Ischia J, Bolton D, Fleshner N, Herrera-Cáceres JO, Klaassen Z, Goldberg H, Chandrasekar T, Alhunaidi O, Tan GH, Nason G, Ajib K, Kulkarni G, Woon D

BJU international2026

DOI: 10.1111/bju.70038 PMID: 41324171

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update)

So AI, Chi K, Danielson B, Fleshner N, Kinnaird A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar SS

Journal of the Canadian Urological Association20253 citations

DOI: 10.5489/cuaj.9240

Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer

Shah NP, Singh A, Higano T, Tilki D, Fleshner N, Nguyen P, Plummer C, Rivas JG, Zhang K, Rendon R

Cardio-Oncology20252 citations

DOI: 10.1186/s40959-025-00318-5

Reply by Authors.

Eigl BJ, Elangovan A, Ghosh S, Kim JO, Thoms J, Bouchard M, Peacock M, Fleshner N, Campbell H, Vigneault E, Vincent F, So A, Cury F, Quon H, Carlson R, Lambert C, Klotz L, Chi K, Brundage M, Pollak M, Rebane L, Chiu L, Courneya KS, Usmani N

The Journal of urology2025

DOI: 10.1097/ju.0000000000004731 PMID: 40928018

Something wrong or missing on this profile? Suggest a correction

Neil Fleshner

Research

Latest papers

Latest funding

External Validation and Comparison of Magnetic Resonance Imaging-based Risk Calculators for Detection of Clinically Significant Prostate Cancer: A Multi-institutional Study Incorporating Transrectal and Transperineal Biopsy Approaches.

Atypical intraductal proliferation in prostate biopsy - a diagnostic grey zone with clinical implications.

131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

Author Correction: Atypical intraductal proliferation in prostate biopsy - a diagnostic grey zone with clinical implications.

Analysis of upper tract urothelial carcinoma in the Asian population.

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update)

Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer

Reply by Authors.

Frequent collaborators

Antonio Finelli

Alexandre Zlotta

Girish Kulkarni

Nathan Perlis

Alejandro Berlin

Bharati Bapat

Robert Hamilton

Bobby Shayegan

Alan So

George Tomlinson

Wassim Kassouf

Vasundara Venkateswaran

Gary Naglie

Libni Eapen

Olli Saarela

Martin Gleave

Eric Vigneault

Jenna Sykes

Michael Brundage

Urban Emmenegger

Kim Chi

Gregory Pond

Laurent Briollais

Chantal Guillemette

Michael Pollak

Shabbir Alibhai

Clement Ma

Michael Ong

Andrew Loblaw

Nawaid Usmani

Himu Lukka

Sebastien Hotte

Murray Krahn

Linda Penn

Peter Black

Brant Inman

ANDREW FEIFER

Ricardo Rendon

David Berman

Robert Siemens